Update shared on08 Oct 2025
Fair value Decreased 4.33%Analysts have lowered their fair value estimate for Ypsomed Holding from CHF 449.37 to CHF 429.92. They cite a more cautious outlook due to softer revenue growth expectations and increased discount rates, despite optimism about the company's leading role in the injectables market.
Analyst Commentary
Recent analyst updates on Ypsomed Holding reflect a mix of optimism about the company’s long-term growth potential and caution stemming from valuation concerns and execution risk. Perspectives are divided as follows:
Bullish Takeaways- Bullish analysts see Ypsomed as a clear leader in the growing injectable market, following its successful pivot away from other business lines.
- Strong structural demand for injectables is expected to support above-average revenue growth and market share gains in the coming years.
- The company’s ability to execute on strategic divestitures is viewed as key to its renewed focus and streamlined operations.
- Some forecasts anticipate meaningful share price appreciation based on sector trends and Ypsomed’s position in high-growth segments.
- Bearish analysts highlight current valuation metrics as stretched and now less attractive given a more cautious sector outlook.
- There are concerns about whether Ypsomed can maintain its momentum amid increasing competition and changing regulatory environments.
- Execution risks, particularly following recent transitions and divestitures, could limit upside potential in the near term.
- Reduced revenue growth expectations and higher discount rates have led to more conservative target prices.
Valuation Changes
- The Fair Value Estimate has decreased from CHF 449.37 to CHF 429.92, reflecting a more cautious outlook.
- The Discount Rate has risen slightly from 4.48% to 4.49%, indicating higher assumed risk in future cash flows.
- Revenue Growth Expectations have fallen significantly, down from 6.13% to 2.28%.
- Net Profit Margin projections have edged down from 26.35% to 25.06%.
- The Future P/E Ratio has increased from 28.24x to 31.75x, suggesting higher valuation multiples despite softer growth forecasts.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.